Cerebral blood flow (CBF) is highly regulated by changes in arterial PCO 2 and arterial PO 2 .
INTRODUCTION
Respiratory-induced changes in the partial pressure of arterial carbon dioxide (PaCO 2 ) and, to a lesser extent, oxygen (PaO 2 ) play a major role in cerebral blood flow (CBF) regulation (9) . Elevations in PaCO 2 (hypercapnia) lead to vasodilatation of cerebral arterioles in the downstream bed and a subsequent increase in CBF, whereas a reduction in PaCO 2 (hypocapnia) leads to vasoconstriction and a subsequent decrease in CBF (28, 65) . A fall in PaO 2 (hypoxia) below a certain threshold (<40 mmHg), also produces cerebral vasodilatation (19) . These arterial blood gases-induced changes in CBF are mediated through changes in cerebrovascular resistance via alterations in the diameter of the vascular smooth muscle, in response to changes in the level of intracellular calcium and/or calcium sensitivity [for review see (22) ]. Cerebrovascular tone is influenced by several chemical substances, including nitric oxide (NO). Nitric oxide (NO), synthesized from the terminal guanidino nitrogen atom(s) of L-arginine in a two step reaction which is catalysed by the enzyme nitric oxide synthase (NOS) (48) , is an important vasoactive factor that dilates the cerebral vasculature. Under normal conditions two isoforms of NOS are expressed in the brain: endothelial derived NOS (eNOS) and neuronal derived NOS (nNOS) (61) although evidence for the role of eNOS versus nNOS in the control of CBF is controversial (3) .
Vasodilatation evoked by NO is initiated by an increase cyclic 3, 5 '-guanosine monophosphate(cGMP) (7) .
Pharmacological blocking agents have been widely used to examine the role of NO during arterial blood gas-induced CBF changes. In a number of studies the cerebral vasodilatory response to hypercapnia and hypoxia has been inhibited by L-arginine analogues (30, 63) , suggesting the involvement of NO; however, results have not been consistent, potentially due to differences in the sensitivity to NO synthase inhibitors within and between species, including humans (56, 66) . This problem is compounded in human-based studies where it is unclear to what extent NO inhibitors are able to cross the blood-brain-barrier (23, 56, 66) .
Consequently, it is possible that the importance of NO found in previous human studies using NO inhibitors is likely underestimated, and no studies to date have examined the potential exchange of NO over the human brain. It should be acknowledged, however, that NO is unlikely to play an exclusive role in the CBF response to hypercapnia as a residual increase in CBF is seen after NOS inhibition (66) . Further it seems unlikely that reduction in NO plays a major role in the CBF response to hypocapnia in humans since NO inhibition does not influence the cerebral vasoconstrictor response to hypocapnia in animals (63) .
In addition to NO the cerebral vasculature is also influenced by a range of other vasoactive factors including potent vasodilators such as adrenomedullin (ADM) (38) and C-type natriuretic peptide (CNP) (53) , and vasoconstrictors such as endothelin-1 (ET-1)(20) and catecholamines which can function as vasoconstrictors or vasodilators depending on dosage and receptor expression (18) . Although other local factors may also influence CBF during such changes in arterial blood gases (3, 6, 9) , the aforementioned vasoactive factorsincluding NO (as indexed by nitrite) -are reliability quantifiable in human blood.
Surprisingly, however, none of these vasoactive substances have been sampled across the human brain during controlled changes in arterial blood gases.
Evidence for a potential involvement of ADM, CNP and endothelin in CBF changes during hypoxia is supported by animal and cultured cells studies showing that ADM (55), CNP (57) and ET-1 (34, 44) expression is substantially upregulated during hypoxia. Evidence for a potential involvement of ADM, CNP and ET-1 in CBF changes during hypercapnia is indirect as no studies that have specifically examined their role. However, given that: i) an increase in blood flow increases shear stress (27) and ii) that shear stress immediately upregulates ADM and CNP expression (10) and suppresses ET-1 expression (41), it is conceivable that increases in ADM and CNP and a decrease in ET-1 may contribute to hypercapnic-induced increases in CBF. Further -again in animal studies -there is evidence for the involvement of catecholamines in CBF increases during hypercapnia (5) and hypoxia (4) . Moreover, recent studies show that there are a myriad of ways in which vasoactive agents interact. For example ADM and CNP can functionally antagonise endothelin-1 (24, 57) .
The examples outlined illustrate the complex manner in which cerebrovascular tone and blood flow is regulated and also the importance of quantifying a range of vasoactive markers. No previous attempt of quantifying a range of potent vasoactive markers has been made in humans. The few human studies that have been completed (26, 60) have only considered the role of individual vasoactive agents and only provide an indirect measure of cerebral levels since blood was procured from peripheral venous samples. Consequently, there is no information that correlates the effect of a variety of vasoactive factors during acute changes in CBF across the human brain. Given the uncertainties regarding endogenous vasoactive agents involved in human CBF regulation during blood gas changes, the main purpose of the present study was to quantify the level of NO and the other aforementioned vasoactive agents in cerebrovascular changes during a series of controlled alterations in PaCO 2 and PaO 2 and to explore correlations between these agents and CBF.
We elected to quantify the contribution of NO by measuring its stable metabolites -nitrite and NOx (nitrite and nitrate) -simultaneously from arterial and internal jugular venous blood to provide insight into NO exchange in the human brain. In addition, we also quantified the potential influence of ADM, CNP, ET-1 and catecholamines (adrenaline and noradrenaline) during blood gas-induced CBF alterations. We hypothesized that hypercapnia and hypoxia, but not hypocapnia, would primarily result in a progressive release of nitrite and NOx from the brain. We also hypothesized that other vasoactive factors would, to a lesser extent, change during these alterations in blood gases.
Specifically, that an increase in the vasodilators ADM, CNP and catecholamines and a decrease in the vasoconstrictor ET-1 would potentially contribute to an increase in CBF during hypercapnia. Moreover an increase in ADM, CNP and catecholamines would contribute to a potential elevation in CBF during hypoxia although the magnitude of the vasodilatation may be offset by an increase in ET-1.
MATERIALS AND METHODS

Subjects:
Twelve healthy individuals [aged 27± 5 (mean ± SD), body mass index 24 ± 4 kg/m 2 [(10 male, 2 female)] volunteered for this study, which was approved by the Lower South Regional Ethics committee and conformed to the standards set by the Declaration of Helsinki. All participants received verbal and written explanation of the experimental procedures, including risks involved in the study, and written informed consent was obtained. Participants were non-smokers, not on any medication and none had a known history of cardiovascular, neurological or respiratory disease. To minimize the potential effect of oestrogen on vascular function, the two female subjects were not pregnant and were studied during the early follicular phase of their menstrual cycle.
Experimental design:
Following full familiarization to the experimental protocol (excluding cannulation), participants arrived at the laboratory (>1week) having abstained from exercise and alcohol for 24h, and having not consumed a heavy meal or items containing caffeine for 4h.
Experimental protocol:
Cannulation During this time the participants also acclimatised to the face mask after which baseline measurements were obtained. Participants then underwent the following tests of cerebral vasoreactivity to CO 2 and O 2 as described below. Following the incremental hypoxia, air breathing was allowed so that baseline measurements could once again be obtained.
Monitoring equipment:
Cerebral blood flow velocity in the right middle cerebral artery was measured using a 2MHz pulsed Doppler ultrasound system (DWL Doppler, Sterling VA, USA) using search techniques described elsewhere (1). In our laboratory, the day-to-day reproducibility (coefficient of variation) of MCAv is 4.5%; this variation is consistent across the CO 2 ranges used in this study (11, 49) . Beat-to-beat arterial blood pressure and heart rate were monitored using finger photoplethysmography (Finometer, TPD Biomedical Instrumentation, The Netherlands) and ECG (Bio Amp, ADInstruments), respectively.
End-tidal CO 2 (PETCO 2 ) was sampled from a leak-free mask and measured by a gas following enzymatic reduction to nitrite (with vanadium chloride in HCl at 94°C as the reductant) using a flow-injection analysis based on the Griess reaction. All samples were tested in duplicate and the intra-assay and inter-assay coefficients of variation (CV's) of nitrite and nitrate were <2% and <3 respectively.
Established methods were used to measure ADM(38), ET-1(31) and catecholamines (15, 17) . ADM was measured by radioimmunoassay as described by Lewis et al (38) . Briefly, 1 ml EDTA plasma was applied to C18 SepPak cartridges and eluted with 80% isopropanolol/0.013MHcl. The elutant was dried under air and reconstituted with buffer Plasma immunoreactive endothelin-1 was measured using an acetic acid extraction technique22 and a modified commercial radioimmunoassay using rabbit antihuman endothelin-1 (Peninsula Laboratories Europe, St. Helens, UK)(31). Briefly, 2 ml EDTA plasma was applied to C18 SepPak cartridges and eluted with 80% isopropanolol in 0.1%TFA, dried under air steam and reconstituted with 0.5mL of 0.1M phosphate buffer.
Endothelin was assayed by adding 100uL of standard or extract containing Endothelin antiserum (cat. Number RAS6901, Bachem USA). The assay was incubated for 3 hours at room temperature. Following incubation, 125 I-labeled endothelin-1 (NEN Life Science Products, Boston, MA, USA) was added, and incubation was continued for an additional 22-24 hours at 4°C. Complexes were precipitated with Amerlex™ donkey antirabbit antibody (Amersham Life Sciences Ltd., Little Chalfont, Bucks., UK) and were counted for radioactivity. All endothelin values were expressed as picograms per milliliter. Using these methods intra-assay and inter-assay CV's were 12.7% at 1.8-3.0 pmol/L and 12.5% at 3.0 pmol/L, respectively; the sensitivity of the assay for endothelin-1 was 0.25 pg/ml. The range for the assay in 200 normal human volunteers in our laboratory was 0.9 ± 2.3pmol/L.
For the catecholamine assay plasma was extracted on alumina and catecholamines were eluted with acetic acid using established techniques (15, 17) . The extracted catecholamines were separated and measured by reverse phase High Performance Liquid Chromatography with electrochemical detection. The reference range for 45 healthy subjects reported by our laboratory is Noradrenaline 47-3800pmol/L and adrenaline <570 pmol//L. The intra and inter-assay CV's were both <6%.
Since plasma CNP levels are very low, therefore difficult to measure, we used the Nterminal CNP assay as an index of CNP. N-terminal CNP (NCNP) is co-secreted with CNP and provides a sensitive and reliable alternative (53) . NT-proCNP was assayed as previously described (52) . Two ml of plasma was extracted on C18 SepPak cartridges and eluted with 2mL of 80% isopropanol in 0.1 % trifluroacetic acid, dried under air and reconstituted with 0.5 mL of phosphate buffer. The extracted NT-CNP was added to primary rabbit antiserum (J39) raised against NT-proCNP-(1-15) (100 µl 1:6,000 diluted antiserum/assay tube). Peptide standards were made from synthetic human proCNP(1-15), taking into account the purity data supplied (Chiron Technologies). Within-and betweenassay coefficients of variation were 6.0% and 7.9%, respectively.
Nitrite and NOx were quantified during air breathing and during each of the CO 2 and O 2 levels. Because of ethical constraints of the amount of blood volume sampled, and the high amount of plasma required for the various assays, ADM, ET-1, NCNP and catecholamines were only quantified during air breathing and during the most severe levels of hypercapnia (8% CO 2 ), hypocapnia (Hypocapnia II) and hypoxia (10% O 2 ).
Calculations: Cerebral arterial and venous oxygen contents (CaO 2 and CvO 2 , respectively)
were calculated using standard equations, as previously used by Hijazi et al. (21) Statistical analysis: All data were analysed using the SPSS social statistics package (Version 12, Surrey, UK). One-way ANOVA was used to assess the statistical differences following interventions, with the Bonferroni-Dunn test used for post-hoc analysis when a significant effect was found. A Pearson correlation analysis was used to determine the relationship between selected variables. All group data are expressed as a mean ± standard deviation (SD). Significance was established at an alpha level of P<0.05.
RESULTS
Incremental and decremental CO 2 protocol:
Incremental hypercapnia caused a progressive increase in PaCO 2 , mean cerebral blood flow velocity (MCAv) and CBF whereas incremental hypocapnia caused a progressive decline in PaCO 2 , MCAv and CBF (Table 1, 2). Whilst there was a significant correlation between MCAv and CBF (r = 0.86; P<0.05),
indicating that MCAv provides a reliable index of CBF it was noted that during 8% CO 2 the relative increase in CBF was ~ 2.5 fold greater than baseline using the Fick principle while the relative increase in MCAv was ~ 1.5 fold greater using Doppler ultrasound (Table   1 ). There was no significant change in mean BP or HR during incremental hypercapnia or hypocapnia ( Table 1) .
Exchange of vasoactive factors:
During incremental hypercapnia, but not hypocapnia, there was an increase in v-a diff for nitrite, indicating a marked release of nitrite from the brain ( Table 3) . A similar pattern was seen for the cerebral v-a diff for NOx although the individual data reveal more variability ( Table 3 ). The cerebral balance data reveal similar changes. For example, MCAv was correlated with the net cerebral nitrite balance (r = 0.78, P < 0.05) and net cerebral NOx balance (r = 0.54, P < 0.05). However, independent analysis of the hypercapnic and hypocapnic data revealed a significant relationship between MCAv and net cerebral nitrite (r = 0.70, P <0.05), but not NOx (r = 0.44, NS), in the hypercapnic range; no correlations were evident between MCAv and net cerebral nitrite or NOx in the hypocapnic range (Figures 1a and b) .
The v-a diff for adrenaline, noradrenaline, ET-1, NCNP and ADM was unchanged between air breathing and 8% CO 2 and between air breathing and Hypocapnia II. However, when the analysis is extended to include the full range of CO 2 alterations in the levels of arterial and venous adrenaline, arterial and venous NCNP and the v-a diff for NCNP was found to be significantly greater during 8% CO 2 than Hypocapnia II (Table 3) .
Correlation analysis across the full range of CO 2 alterations revealed several findings. Table 2) . Whilst MCAv, CBF and MAP were unchanged (Tables 1 and 2 ) at both 12 and 10% O 2 , HR was elevated (P <0.05).
During incremental hypoxia, cerebral v-a diff for nitrite, but not NOx, was decreased, indicating a selective uptake of nitrite in the brain (Table 3) .
There was no correlation between MCAv and the cerebral balance for nitrite or NOx.
Similar to the CO 2 challenges, the v-a diff for adrenaline, noradrenaline, ET-1, NCNP and ADM did not change between air breathing and 10% O 2 (Table 3) , indicating no cerebral release or uptake of these vasoactive factors with hypoxia. However, the levels of arterial and venous adrenaline were significantly higher during 10% O 2 than air breathing, suggesting a systemic release of adrenaline, despite no change the MCAv (Tables 1 and 3) .
DISCUSSION
The major findings of the present study were that: 1) when compared to baseline there was no cerebral uptake or release of other vasoactive factors (adrenomedullin, ET-1, NCNP and catecholamines) during blood gas alterations although when the full range of CO 2 stimuli (i.e. Hypocapnia II to 8% CO 2 ) was examined there was a relative increase in release of NCNP from the brain with progressive hypercapnia; 2) there was a marked release of nitrite from the brain during hypercapnic-induced elevations in CBF, whereas no changes occurred during hypocapnic-induced decreases in CBF; and 3) in contrast to our original hypothesis, whilst CBF was unchanged in acute hypoxia, there was a selective uptake of nitrite in the brain. On the basis of our experimental approach, whilst acknowledging the limitation of correlational analysis not necessary meaning cause and effect, these findings indicate there is a differential exchange of NO during hypercapnia and hypoxia across the human brain. On the basis that NCNP is a reliable index CNP our data indicates that CNP release from the brain may also play a supplementary role in regulating CBF during changes in arterial PCO 2 .
Arterial PCO 2 and nitrite exchange
Calculation of NO exchange kinetics directly across the human brain via simultaneous measurement of arterial and internal jugular venous blood provided, for the first time, evidence to indicate a net release of nitrite from the brain during hypercapnia, whereas no changes were evident during hypocapnia. These changes occurred without the confounding influence of pharmacological agents. Within the brain, NO is produced in the endothelium as well as neuronal tissue, i.e., neurons, perivascular nerves and astrocytes. In pigs, hypercapnia provokes an increase in CBF and in endothelial NO synthase mRNA expression; both were blunted by a nonselective NO synthase inhibitor but not by a selective neuronal NO synthase inhibitor, (45) suggesting that the CBF increase is associated with an increase in endothelial rather than neuronal NO. Conversely, in rodents, a neuronal NO was the more important source (47) . Collectively, although the precise contribution of endothelial NO synthase and neuronal NO synthase during hypercapnia is still unclear (45), previous animal and human studies indicate that endothelial NO synthase is an important, although not exclusive, mediator of hypercapnic-induced alterations in CBF in healthy young humans (36) . It should be noted that the index of NO used in the present study was confined to endothelial NO synthase (eNOS) yet the observed increase in CBF represents a collective response. Given the wide variety of sources of cerebral NO we can not exclude the possibility our nitrite measurements may underestimate the true release of cerebral NO. In addition, we cannot exclude the potential role of a shear-stress response in mediating a release of NO (42) . Because hypercapnia is associated with an increase in CBF and concomitant release of plasma nitrite, and because fluid shear-stress evokes a stimulus dependent increase in cerebral NO production (42) , it seems reasonable to suggest that the progressive release of nitrite indicates, in part, that there is a hypercapnic-induced shear-stress response and subsequent NO release. It was not the goal of our study to separate these potential mechanisms; however, detailed animal studies are warranted to further delineate the influence of shear-stress from hypercapnic-induced NO vasodilatation.
Acute hypoxia, CBF and nitrite exchange
The observation that CBF did not increase during acute poikilopcapnic hypoxia (i.e where P ET CO 2 is uncontrolled) is consistent with previous human studies (2) . The lack of an increase in CBF in the present study suggests that the cerebral vasoconstriction induced by the fall in PaCO 2 was sufficient to counteract any vasodilatory effects of hypoxia. Contrary to our original hypothesis, there was a clear uptake of nitrite in acute hypoxia. There is only one human study (62) to which we can compare our findings, which reported an increase in CBF during 20 min of poikilocapnic hypoxia (SpO 2 = 80%) that was blunted by L-NMMA (62), suggesting a hypoxia induced release of NO. Our results are not consistent with this, although differences in methodological design, including the use of magnetic resonance imaging, a longer duration of hypoxia, and the use of an L-arginine analogue, make direct comparison difficult. In support of our findings, a recent study in pigs (30) employed an electronic NO sensor to directly measure cerebral NO concentration and reported a fall in NO concentration after 180s of hypoxia. Since O 2 is essential for the formation of NO via NO synthase, these authors proposed that the fall in NO was due to hypoxic-induced reduction in NO synthesis (30) .
The possibility exists that the level of hypoxia in the present study may not have been sufficient to elicit NO release. Nitrite has been considered as an index of NO bioavailabilty, in particular eNOS activity (33) . Importantly, since nitrite can spontaneously decompose to NO when PaO 2 levels are low (~ 40-20 mmHg) it has been considered a 'reservoir' for NO (16). We observed that during the most severe hypoxic stimulus, PaO 2 fell to 43 mmHg (SaO 2 ≅ 78%) and PvO 2 to 26 mmHg (SvO 2 ≅ 50%, Table 3 ). The mechanism of action and location of the O 2 sensor is not completely known but is likely downstream of the terminal arterioles (25) . If the O 2 sensor was located closer to the arterial than venular end of the capillary network, it is possible that at the point at which it was sensed, the level of PaO 2 in the present study was not severe enough to stimulate NO release. Most importantly, it should be noted that NO is not the only source of nitrite in the blood. For example, it has been reported that red-blood cells have functional eNOS and can, themselves, produce NO(32). Moreover, NO binds avidly to hemoglobin. Therefore, much of the NO entering the blood might be as HbNO not nitrite. Feature studies combined detailed measured of red blood cell and hemoglobin-derived nitrite levels are needed to clarify and extend our findings.
The role of other endothelial markers during arterial PCO 2 and PO 2 changes
With the exception of CNP, during step changes in PCO 2 or PO 2 , there was no cerebral release or uptake of ET-1, ADM or catecholamines. Interestingly, there was a graded increase in arterial, venous and v-a diff for NCNP was apparent between the hypocapnia and hypercapnia (8% CO 2 ). These findings indicate that the systemic and cerebral vasculature is able release CNP in response to progressive hypercapnia, providing the range of CO 2 stimuli is sufficiently wide. Considerable physiological evidence suggests that vasoactive factors not only act independently but may also modulate each other. For instance there are reports of complementary cross-talk between CNP and NO in mounted tissue preparations (39) . Undoubtedly, such interactions add to the complexity of analyzing vasoactive responses during CBF changes and it was not the purpose of this paper to examine these in detail. However, it is worth noting that during CO 2 alterations we saw parallel changes in cerebral nitrite release and cerebral NCNP release (P = 0.07). Whilst interpreting this trend cautiously, it is of interest that both NO and NCNP are derived from the endothelium (9, 39), both the NO and CNP pathways are stimulated by shear stress (10, 42) , and both substances were associated with cerebral vasodilatation in response to increasing CO 2 .
These commonalities coupled with the aforementioned findings from mounted tissue preparations (39) suggest that there is a cooperative interaction between the release of NO and CNP in the cerebral vasculature during CO 2 -induced blood flow changes which warrants further investigation.
Despite the absence of a v-a diff for catecholamines it is of interest that an increase in arterial and venous adrenaline was observed across the hypocapnic to hypercapnic gas range as well as during the hypoxic interventions. We considered whether the carotid body might be involved in this response. The carotid bodies, apart from their fundamental role in the hypoxic ventilatory response (40) also play a role in the hypercapnic ventilatory response (12) . Moreover, carotid body stimulation evokes an increase in sympathetic nerve activity to muscle, splanchnic and renal vascular beds thus contributes to the significant interactions between the ventilatory and cardiovascular control (40) . These findings raise the possibility that the increase in systemic adrenaline might have occurred secondary to carotid body stimulation although, the absence of a simultaneous increase in noradrenaline goes against this suggestion.
Methodological considerations and Limitations
The technique of measuring radial arterial -internal jugular venous differences provides important information regarding the net release and net uptake of vasoactive agents in the human brain. However, it is acknowledged that a-v gradients do not provide information regarding the movement of vasoactive substances outside the blood circulation e.g. our peptide markers only indirectly reflect levels in the cerebrospinal fluid and/or brain tissue.
Further, they do not provide any insight as to whether a net increase in a given vasoactive agent is due to an increase in production/release or inhibition of uptake. It should be noted that the techniques used in the present study i.e. arterial and venous cannulation were invasive and represent a novel approach to quantifying cerebral vasoactive agents in conscious humans.
It has been widely accepted that the internal jugular venous versus external vertebral venous system represents the major outflow for intracranial blood. However, several authors have shown that venous outflow may be influenced by posture and anatomical variability (14, 54) raising the potential for non-jugular venous drainage to result in an underestimation of vasoactive agents. Unfortunately angiographic studies were not performed in this study however it is noted that Doepp et al (14) reported that the internal jugular veins were the main source of venous drainage in 72% of their healthy volunteers when positioned supine.
It is recognized that our study only quantified a selection of vasoactive factors as justified in the introduction. It was not possible to measure any additional factors as ethical constraints limit the total volume of blood that can be drawn from human subjects.
Although we used Doppler ultrasound to measure flow velocity, rather than blood flow, in the MCA, the majority of research suggests that MCAv is a reliable index of CBF (51 thus, the plasma NOx concentrations may not sensitively reflect acute changes in NO activity (35) .
In the present study the cerebrovascular responses to hypoxia were studied under poikilopcapnic conditions. It would be of interest to examine the hypoxic-induced changes in ventilation and CBF under isocapnic conditions i.e. with the arterial PCO 2 level controlled, in order to remove the confounding influence of hypocapnia; however, since both the conditions of hypocapnia per se resulted in no change in the majority in the vasoactive substances, the influence of hypocapnia alone would seem not to have a major regulatory role in regulation of the quantifiable vasoactive substances across the brain.
In addition to NO, it should be noted that cerebrovascular CO 2 reactivity is primarily mediated by pH, and can also be modulated by cyclooxygenase activity (8) . Interestingly, there is evidence of interactions between cyclooxygenase activity and NO. For example several authors have shown that NO and prostacyclin-a cyclooxygenase derivative and an important dilator prostanoid in the cerebral circulation act in a permissive manner i.e. the hypercapnic vascular response to NO requires the presence of prostacyclin to work (37, 64) Given these findings it was unfortunate that, because of lack of plasma and some doubts of the reliability of the use of a down-steam metabolite as an index of prostacyclin, we not able to make these additional measurements. That said, the relative roles of NO and prostanoids in hypercapnic cerebral dilatation, in humans may be age dependent since there is evidence in pigs that the contribution of NO versus prostacyclin to hypercapnic cerebrovascular dilatation increases with age (67) . In light of these findings it is conceivable that significant increases in prostacyclin during hypercapnic vasodilation may not have observed in the present study since adult humans were studied.
In conclusion, in the present study, hypercapnia is associated with a net release of nitrite from the brain whereas hypoxia is associated with a net uptake of nitrite. There was no net cerebral release or uptake of adrenaline, noradrenaline, ET-1 or ADM during CO 2 and O 2 alterations; however, cerebral release of NCNP was evident when a wide range of CO 2 alterations was examined. These data indicate that there is a differential exchange of NO across the brain during hypercapnia and hypoxia and CNP may play a complimentary role in CO 2 -induced CBF changes.
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